The HSP90 inhibitor ganetespib: A potential effective agent for Acute Myeloid Leukemia in combination with cytarabine

Leukemia Research

Volumn 39, Issue 6, 2015, Pages 617-624

  Lazenby, M ^a   Hills, R ^a   Burnett, A K ^a   Zabkiewicz, J ^a  

^a CARDIFF UNIVERSITY   (United Kingdom)

Author keywords

AML; Ganetespib; HSP90

Indexed keywords

CYTARABINE; GANETESPIB; HEAT SHOCK PROTEIN 90 INHIBITOR; PROTEIN KINASE B; ANTINEOPLASTIC AGENT; HEAT SHOCK PROTEIN 90; TRIAZOLE DERIVATIVE;

ACUTE MYELOBLASTIC LEUKEMIA; ADULT; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER RESISTANCE; CELL DEATH; CELL PROTECTION; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG EFFECT; DRUG EFFICACY; DRUG POTENTIATION; DRUG SAFETY; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; LEUKEMIA CELL; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MONOTHERAPY; PRIMARY TUMOR; PRIORITY JOURNAL; YOUNG ADULT; ANTAGONISTS AND INHIBITORS; BLAST CRISIS; DOSE RESPONSE; HL 60 CELL LINE; LEUKEMIA, MYELOID, ACUTE; METABOLISM; PATHOLOGY;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BLAST CRISIS; CYTARABINE; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HL-60 CELLS; HSP90 HEAT-SHOCK PROTEINS; HUMANS; LEUKEMIA, MYELOID, ACUTE; MALE; PROTO-ONCOGENE PROTEINS C-AKT; TRIAZOLES;

EID: 84929507626     PISSN: 01452126     EISSN: 18735835     Source Type: Journal    
DOI: 10.1016/j.leukres.2015.03.016     Document Type: Article

References (42)

1. Kubota H., Yamamoto S., Itoh E., Abe Y., Nakamura A., Izumi Y., et al. Increased expression of co-chaperone HOP with HSP90 and HSC70 and complex formation in human colonic carcinoma. Cell Stress Chaperones 2010, 15:1003-1011.
2. Rohl A., Rohrberg J., Buchner J. The chaperone Hsp90: changing partners for demanding clients. Trends Biochem Sci 2013, 38:253-262.
3. Flandrin P., Guyotat D., Duval A., Cornillon J., Tavernier E., Nadal N., et al. Significance of heat-shock protein (HSP) 90 expression in acute myeloid leukemia cells. Cell Stress Chaperones 2008, 13:357-364.
4. Hong D.S., Banerji U., Tavana B., George G.C., Aaron J., Kurzrock R. Targeting the molecular chaperone heat shock protein 90 (HSP90): lessons learned and future directions. Cancer Treat Rev 2013, 39:375-387.
5. da Silva V.C., Ramos C.H. The network interaction of the human cytosolic 90kDa heat shock protein Hsp90: a target for cancer therapeutics. J Proteomics 2012, 75:2790-2802.
6. Mahalingam D., Swords R., Carew J.S., Nawrocki S.T., Bhalla K., Giles F.J. Targeting HSP90 for cancer therapy. Br J Cancer 2009, 100:1523-1529.
7. Polier S., Samant R.S., Clarke P.A., Workman P., Prodromou C., Pearl L.H. ATP-competitive inhibitors block protein kinase recruitment to the Hsp90-Cdc37 system. Nat Chem Biol 2013, 9:307-312.
8. Cheung C.H., Chen H.H., Cheng L.T., Lyu K.W., Kanwar J.R., Chang J.Y. Targeting Hsp90 with small molecule inhibitors induces the over-expression of the anti-apoptotic molecule, survivin, in human A549, HONE-1 and HT-29 cancer cells. Mol Cancer 2010, 9:77.
9. Dempsey N.C., Leoni F., Ireland H.E., Hoyle C., Williams J.H. Differential heat shock protein localization in chronic lymphocytic leukemia. J Leukoc Biol 2010, 87:467-476.
10. Mjahed H., Girodon F., Fontenay M., Garrido C. Heat shock proteins in hematopoietic malignancies. Exp Cell Res 2012, 318:1946-1958.
11. Fredly H., Reikvam H., Gjertsen B.T., Bruserud O. Disease-stabilizing treatment with all-trans retinoic acid and valproic acid in acute myeloid leukemia: serum hsp70 and hsp90 levels and serum cytokine profiles are determined by the disease, patient age, and anti-leukemic treatment. Am J Hematol 2012, 87:368-376.
12. Thomas X., Campos L., Mounier C., Cornillon J., Flandrin P., Le Q.H., et al. Expression of heat-shock proteins is associated with major adverse prognostic factors in acute myeloid leukemia. Leuk Res 2005, 29:1049-1058.
13. Li Y., Zhang T., Schwartz S.J., Sun D. New developments in Hsp90 inhibitors as anti-cancer therapeutics: mechanisms, clinical perspective and more potential. Drug Resist Updat 2009, 12:17-27.
14. Roe S.M., Prodromou C., O'Brien R., Ladbury J.E., Piper P.W., Pearl L.H. Structural basis for inhibition of the Hsp90 molecular chaperone by the antitumor antibiotics radicicol and geldanamycin. J Med Chem 1999, 42:260-266.
15. Proia D.A., Bates R.C. Ganetespib and HSP90: translating preclinical hypotheses into clinical promise. Cancer Res 2014, 74:1294-1300.
16. Ying W., Du Z., Sun L., Foley K.P., Proia D.A., Blackman R.K., et al. Ganetespib, a unique triazolone-containing Hsp90 inhibitor, exhibits potent antitumor activity and a superior safety profile for cancer therapy. Mol Cancer Ther 2012, 11:475-484.
17. Shimamura T., Perera S.A., Foley K.P., Sang J., Rodig S.J., Inoue T., et al. Ganetespib (STA-9090), a nongeldanamycin HSP90 inhibitor, has potent antitumor activity in in vitro and in vivo models of non-small cell lung cancer. Clin Cancer Res 2012, 18:4973-4985.
18. He S., Zhang C., Shafi A.A., Sequeira M., Acquaviva J., Friedland J.C., et al. Potent activity of the Hsp90 inhibitor ganetespib in prostate cancer cells irrespective of androgen receptor status or variant receptor expression. Int J Oncol 2013, 42:35-43.
19. Proia D.A., Foley K.P., Korbut T., Sang J., Smith D., Bates R.C., et al. Multifaceted intervention by the Hsp90 inhibitor ganetespib (STA-9090) in cancer cells with activated JAK/STAT signaling. PLoS ONE 2011, 6:e18552.
20. Choi H.K., Lee K. Recent updates on the development of ganetespib as a Hsp90 inhibitor. Arch Pharm Res 2012, 35:1855-1859.
21. Goldman J.W., Raju R.N., Gordon G.A., El-Hariry I., Teofilivici F., Vukovic V.M., et al. A first in human, safety, pharmacokinetics, and clinical activity phase I study of once weekly administration of the Hsp90 inhibitor ganetespib (STA-9090) in patients with solid malignancies. BMC Cancer 2013, 13:152.
22. Socinski M.A., Goldman J., El-Hariry I., Koczywas M., Vukovic V., Horn L., et al. A multicenter phase II study of ganetespib monotherapy in patients with genotypically defined advanced non-small cell lung cancer. Clin Cancer Res 2013, 19:3068-3077.
23. Chou T.C., Talalay P. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 1984, 22:27-55.
24. Pearn L., Fisher J., Burnett A.K., Darley R.L. The role of PKC and PDK1 in monocyte lineage specification by Ras. Blood 2007, 109:4461-4469.
25. Sharma K., Vabulas R.M., Macek B., Pinkert S., Cox J., Mann M., et al. Quantitative proteomics reveals that Hsp90 inhibition preferentially targets kinases and the DNA damage response. Mol Cell Proteomics 2012, 11:M111.
26. Frelin C., Imbert V., Griessinger E., Peyron A.C., Rochet N., Philip P., et al. Targeting NF-kappaB activation via pharmacologic inhibition of IKK2-induced apoptosis of human acute myeloid leukemia cells. Blood 2005, 105:804-811.
27. Newman B., Liu Y., Lee H.F., Sun D., Wang Y. HSP90 inhibitor 17-AAG selectively eradicates lymphoma stem cells. Cancer Res 2012, 72:4551-4561.
28. Okawa Y., Hideshima T., Steed P., Vallet S., Hall S., Huang K., et al. SNX-2112, a selective Hsp90 inhibitor, potently inhibits tumor cell growth, angiogenesis, and osteoclastogenesis in multiple myeloma and other hematologic tumors by abrogating signaling via Akt and ERK. Blood 2009, 113:846-855.
29. Rajan A., Kelly R.J., Trepel J.B., Kim Y.S., Alarcon S.V., Kummar S., et al. A phase I study of PF-04929113 (SNX-5422), an orally bioavailable heat shock protein 90 inhibitor, in patients with refractory solid tumor malignancies and lymphomas. Clin Cancer Res 2011, 17:6831-6839.
30. Walsby E.J., Lazenby M., Pepper C.J., Knapper S., Burnett A.K. The HSP90 inhibitor NVP-AUY922-AG inhibits the PI3K and IKK signalling pathways and synergizes with cytarabine in acute myeloid leukaemia cells. Br J Haematol 2013, 161:57-67.
31. Wu X., Marmarelis M.E., Hodi F.S. Activity of the heat shock protein 90 inhibitor ganetespib in melanoma. PLoS ONE 2013, 8:e56134.
32. Liu H., Lu J., Hua Y., Zhang P., Liang Z., Ruan L., et al. Targeting heat-shock protein 90 with ganetespib for molecularly targeted therapy of gastric cancer. Cell Death Dis 2015, 6:e1595.
33. Kamal A., Thao L., Sensintaffar J., Zhang L., Boehm M.F., Fritz L.C., et al. A high-affinity conformation of Hsp90 confers tumour selectivity on Hsp90 inhibitors. Nature 2003, 425:407-410.
34. Siendones E., Barbarroja N., Torres L.A., Buendia P., Velasco F., Dorado G., et al. Inhibition of Flt3-activating mutations does not prevent constitutive activation of ERK/Akt/STAT pathways in some AML cells: a possible cause for the limited effectiveness of monotherapy with small-molecule inhibitors. Hematol Oncol 2007, 25:30-37.
35. Chen Y., Chen J., Loo A., Jaeger S., Bagdasarian L., Yu J., et al. Targeting HSF1 sensitizes cancer cells to HSP90 inhibition. Oncotarget 2013, 4:816-829.
36. Davenport E.L., Zeisig A., Aronson L.I., Moore H.E., Hockley S., Gonzalez D., et al. Targeting heat shock protein 72 enhances Hsp90 inhibitor-induced apoptosis in myeloma. Leukemia 2010, 24:1804-1807.
37. Whitesell L., Lindquist S.L. HSP90 and the chaperoning of cancer. Nat Rev Cancer 2005, 5:761-772.
38. Powers M.V., Clarke P.A., Workman P. Dual targeting of HSC70 and HSP72 inhibits HSP90 function and induces tumor-specific apoptosis. Cancer Cell 2008, 14:250-262.
39. Saif M.W., Erlichman C., Dragovich T., Mendelson D., Toft D., Burrows F., et al. Open-label, dose-escalation, safety, pharmacokinetic, and pharmacodynamic study of intravenously administered CNF1010 (17-(allylamino)-17-demethoxygeldanamycin [17-AAG]) in patients with solid tumors. Cancer Chemother Pharmacol 2013, 71:1345-1355.
40. Reikvam H., Nepstad I., Sulen A., Gjertsen B.T., Hatfield K.J., Bruserud O. Increased antileukemic effects in human acute myeloid leukemia by combining HSP70 and HSP90 inhibitors. Expert Opin Investig Drugs 2013, 22:551-563.
41. Quanz M., Herbette A., Sayarath M., de Koning L., Dubois T., Sun J.S., et al. Heat shock protein 90alpha (Hsp90alpha) is phosphorylated in response to DNA damage and accumulates in repair foci. J Biol Chem 2012, 287:8803-8815.
42. Moulick K., Ahn J.H., Zong H., Rodina A., Cerchietti L., Gomes DaGama E.M., et al. Affinity-based proteomics reveal cancer-specific networks coordinated by Hsp90. Nat Chem Biol 2011, 7:818-826.